CoChat

CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas

Open access

Published version of a preprint

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Abstract Purpose: Angiosarcomas are soft tissue sarcomas with endothelial differentiation and vasoformative capacity. Most angiosarcomas show strong constitutive expression of the endothelial adhesion receptor CD31/PECAM-1 pointing to an important role of this molecule. However, the biological function of CD31 in angiosarcomas is unknown. Experimental Design: The expression levels of CD31 in angiosarcoma cells and its effects on cell viability, colony formation, and chemoresistance were evaluated in human angiosarcoma clinical samples and in cell lines through isolation of CD31high and CD31low cell subsets. The redox-regulatory CD31 function linked to YAP signaling was determined using a CD31-blocking antibody and siRNA approach and was further validated in CD31-knockout endothelial cells. Results: We found that most angiosarcomas contain a small CD31low cell population. CD31low cells had lost part of their endothelial properties and were more tumorigenic and chemoresistant than CD31high cells due to more efficient reactive oxygen species (ROS) detoxification. Active downregulation of CD31 resulted in loss of endothelial tube formation, nuclear accumulation of YAP, and YAP-dependent induction of antioxidative enzymes. Addition of pazopanib, a known enhancer of proteasomal YAP degradation resensitized CD31low cells for doxorubicin resulting in growth suppression and induction of apoptosis. Conclusions: Human angiosarcomas contain a small aggressive CD31low population that have lost part of their endothelial differentiation programs and are more resistant against oxidative stress and DNA damage due to intensified YAP signaling. Our finding that the addition of YAP inhibitors can resensitize CD31low cells toward doxorubicin may aid in the rational development of novel combination therapies to treat angiosarcomas. Clin Cancer Res; 24(2); 460–73. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-1778

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 1

  1. Weiss, 2008, Malignant vascular tumors, 703

Cited by

See all 52

Metadata

Authors
Venkataramani, V., Küffer, S., Cheung, K. C. P., Jiang, X., Trümper, L., Wulf, G. G., & Ströbel, P.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Universitätsmedizin Göttingen (DE)
  • Queen Mary University of London (GB)
Corresponding author
Venkataramani, Vivek
Venue
Clinical Cancer Research
Published
2018-01-15
Volume
24
Issue
2
Pages
460-473
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2766581018
Cited by
50
References
46
Citations by year
2026: 4 · 2025: 9 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 8 · 2020: 3 · 2019: 7 · 2018: 5
FWCI
1.81
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, other-oa)
Funders
NCI (P30 CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Vascular Tumors and Angiosarcomas
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
Keywords
angiosarcoma, YAP signaling, chemoresistance, doxorubicin resistance, pazopanib, reactive oxygen species scavenging, oxidative stress, endothelial differentiation, tumor heterogeneity, antioxidant enzymes, combination therapy
MeSH terms
Catalase, Cell Survival, Doxorubicin, Hemangiosarcoma, Humans, Immunohistochemistry, Models, Biological, Neovascularization, Pathologic, Oxidation-Reduction, Biomarkers, Gene Expression, Oxidative Stress, Drug Resistance, Neoplasm, Platelet Endothelial Cell Adhesion Molecule-1, RNA, Small Interfering, Endothelial Cells, Cell Line, Tumor, Gene Knockdown Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1778
The paper
Venkataramani, V., Küffer, S., Cheung, K. C. P., Jiang, X., Trümper, L., Wulf, G. G., & Ströbel, P. (2018). CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1778

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.